Guardant Health Reports Q3 2024 Financial Results
Guardant Health, Inc. (NASDAQ: GH), a pioneer in precision oncology, has announced its financial results for the third quarter of 2024. The company recorded a remarkable revenue of $191.5 million for this period, marking a significant 34% increase over the same quarter in the previous year. This growth showcases the efficacy and demand for Guardant Health’s innovative testing solutions and the overall positive response from the oncology community.
Key Financial Highlights
In the recently concluded quarter, Guardant Health reported several notable achievements:
- The revenue of $191.5 million reflects a solid increase from $143.0 million in Q3 2023.
- Clinical tests accounted for 53,100, excluding the Shield tests, while biopharma tests reached 10,500, demonstrating increases of 21% and 40% respectively.
- The average selling price (ASP) for the Guardant360 test surpassed $3,000, an encouraging sign of its market value.
- The annual revenue guidance for 2024 has been revised upwards to a range of $720 million to $725 million, indicating an expected growth of 28% to 29% compared to 2023.
- Free cash flow improved to $(55) million from $(80) million year-on-year.
- Revised annual free cash flow guidance for 2024 is now $(265) million to $(275) million, marking a $70 million to $80 million improvement from last year.
Operational Achievements
Guardant Health achieved several key objectives during the quarter, maintaining its leadership in the oncology sector:
- The successful launch of the Shield IVD saw a strong positive reception from both physicians and patients, enhancing the company’s portfolio.
- Medicare pricing for the Shield tests has been set at $920 as of early this quarter.
- Policy updates from CMS aim to alleviate cost-sharing burdens for patients undergoing follow-up colonoscopies post-blood-based screening.
- Guardant Health also announced a price increase for its TissueNext service from $3,100 to $3,500 effective from the start of the following year.
- Collaboration with Policlinico Gemelli in Italy has been established, expanding testing capabilities for advanced cancer patients in Europe.
- Notably, research published in Nature Medicine emphasized that patients treated using the Guardant360 CDx test demonstrated twice the survival rates compared to traditional methods.
Looking Ahead: Guidance for 2024
As Guardant Health builds on its Q3 momentum, the company projects its total revenue for the full year to be between $720 million to $725 million. This is an upgrade from the earlier forecast of $690 million to $700 million.
The company expects to maintain a non-GAAP gross margin excluding screening charges between 61% to 63%. Furthermore, total non-GAAP operating expenses are expected to range from $720 million to $730 million, either reflecting a steady or minor decrease from previous levels.
For free cash flow, the anticipated range remains $(265) million to $(275) million, an improvement compared to previous forecasts and historical performance from last year.
Guardant Health: Company Overview
Founded in 2012, Guardant Health is deeply committed to transforming cancer care and improving patient outcomes through its advanced insights provided via blood and tissue tests, coupled with real-world data and artificial intelligence analytics. This company’s products are designed to help physicians diagnose cancer earlier, monitor recurrence, and tailor treatment strategies for advanced cancer patients. To learn more about their initiatives and offerings, visit their website and follow them on social platforms.
Frequently Asked Questions
What financial performance did Guardant Health report for Q3 2024?
Guardant Health reported a revenue of $191.5 million for Q3 2024, a 34% increase from the previous year.
How many tests did Guardant Health conduct in Q3 2024?
The company conducted 53,100 clinical tests and 10,500 biopharma tests, showing increases of 21% and 40% year-on-year respectively.
What changes have been made to Guardant Health’s revenue guidance?
The revenue guidance has been raised to $720 million to $725 million for 2024, up from the previous estimate of $690 million to $700 million.
What are the significant operational highlights mentioned?
Significant highlights include the successful launch of Shield IVD, Medicare pricing for Shield tests, and entering a partnership with Policlinico Gemelli in Italy.
What is the non-GAAP gross margin expectation for 2024?
Guardant Health expects the non-GAAP gross margin excluding screening to be between 61% and 63% for 2024.
